RTM receives marketing authorisation for Fludeoxyglucose (18F)

We are happy to announce that RTM has received marketing authorization for 18F-FDG of 17 July 2018.

Fludeoxyglucose (18F) RTM 200 MBq/ml, solution for injection will become commercially available in The Netherlands in October, with roll-out to Belgium and Germany planned in 2019.

RTM receives marketing authorisation for Fludeoxyglucose (18F)

Other news

RTM added as distributor NeuraCeq®

RTM added as distributor NeuraCeq®

Exciting news! Life Molecular Imaging’s NeuraCeq® 300 MBq/ml solution for injection (florbetaben 18F...

Read more

LinkedIn post Isologic goes electric

LinkedIn post Isologic goes electric

🔌Isologic Goes Electric! We are excited to announce the expansion of our electric fleet with the a...

Read more

ABX has received marketing authorisation for the radiotracer Radelumin® in Germany

ABX has received marketing authorisation for the radiotracer Radelumin® in Germany

ABX has received marketing authorisation for the radiotracer Radelumin® in Germany! This marks the 8...

Read more

First Patient Dosed in Phase II Study of TLX250-CDx in Triple-Negative Breast Cancer

First Patient Dosed in Phase II Study of TLX250-CDx in Triple-Negative Breast Cancer

The below product is manufactured at RTM First Patient Dosed in Phase II Study of TLX250-CDx in Tri...

Read more

Interested in a collaboration?

Contact us to discuss the possibilities.